Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

Gut

Volumn 41, Issue 3, 1997, Pages 366-370

  Salcedo, J ^a   Keates, S ^b   Pothoulakis, C ^b   Warny, M ^b   Castagliuolo, I ^b   LaMont, J T ^b   Kelly, C P ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Clostridium difficile; Diarrhoea; IgG; Immunotherapy; Toxin

Indexed keywords

ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN G; METRONIDAZOLE; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANTIBODY BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLITIS; CYTOTOXICITY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS;

EID: 0030763467     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.41.3.366     Document Type: Article

References (41)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
2. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-10.
3. Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease. Microb Pathog 1994; 17: 1-12.
4. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988; 1: 1-18.
5. Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD. Biological activities of toxins A and B of Clostridium difficile. Infect Immun 1982; 35: 1147-50.
6. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonie epithelium in vitro. J Clin Invest 1995; 95: 2004-11.
7. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987; 93: 273-9.
8. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, et al. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 1990; 58: 480-8.
9. Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994; 93: 1257-65.
10. Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C, LaMont JT. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology 1989; 97: 1186-92.
11. von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M. Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B. Med Microbiol Immunol (Berl) 1990; 179: 271-9.
12. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995; 375: 500-3.
13. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, et al. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 1995; 270: 13952-6.
14. Kelly CP. Immune response to Clostridium difficile. Eur J Gastroenterol Hepatol 1996; 8: 1048-53.
15. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992; 102: 35-40.
16. Nakamura S, Mikawa M, Nakashio S, Takabatake M, Okado I, Yamakawa K, et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981; 25: 345-51.
17. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983; 148: 93-100.
18. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13: 97-101.
19. Aronsson B, Granstrom M, Mollby R, Nord CE. Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods 1983; 60: 341-50.
20. Bacon AE III, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhoea. Diagn Microbiol Infect Dis 1994; 18: 205-9.
21. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gammaglobulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633-7.
22. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16 (suppl 4): S239-44.
23. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-9.
24. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996; 40: 373-9.
25. Pothoulakis C, Barone LM, Ely R, Faris B, Clark ME, Franzblau C, et al. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem 1986; 261: 1316-21.
26. Kelly CP, LaMont JT. Treatment of Clostridium difficile diarrhoea and colitis. In: Wolfe MM, ed. Gastrointestinal pharmacotherapy. Philadelphia: WB Saunders, 1993; 199-212.
27. Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, Showalter DP. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992; 127: 847-52.
28. Morris LL, Villalba MR, Glover JL. Management of pseudomembranous colitis. Am Surg 1994; 60: 548-51.
29. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-4.
30. Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995; 38: 1033-8.
31. Bender BS, Bennett R, Laughon BE, Greenough WB III, Gaydos C, Sears SD, et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986; ii: 11-3.
32. McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhoea in a cohort of general medicine patients. Am J Infect Control 1995; 23: 295-305.
33. Schwab R, Walters CA, Weksler ME. Host defense mechanisms and aging. Semin Oncol 1989; 16: 20-7.
34. Weksler ME. Immune senescence. Ann Neurol 1994; 35 (suppl): S35-7.
35. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991; 59: 1192-5.
36. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987; 55: 2984-92.
37. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1941; 59: 2215-8.
38. Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis [letter]. Lancet 1993; 341: 701-2.
39. Hassett J, Meyers S, McFarland L, Mulligan ME. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 1995; 20 (suppl 2): S266-8.
40. Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol 1982; 2: 7S-14S.
41. Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB, Theoharides TC, et al. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest 1991; 88: 119-25.